Analyst consensus rating
Kyntra Bio Analyst Rating: Buy
Direct answer
Kyntra Bio's consensus rating is Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $38.50.
Forecast evidence checked October 19, 2026.
Get free Kyntra Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.85
- Average price target
- $38.50
- High price target
- $43.00
- Low price target
- $35.00
- Low target gap
- +621.6%
- Target upside
- +693.8%
- High target gap
- +786.6%
- Target range width
- 164.9%
- Consensus rating
- Buy
- Analysts
- 4
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Kyntra Bio?
Kyntra Bio has a verified Buy consensus. The same dataset has an average price target of $38.50.
How far are Kyntra Bio's low and high targets from the recorded price?
The low target implies +621.6%, while the high target implies +786.6%.
How many analysts are included in Kyntra Bio's consensus?
The verified consensus includes 4 analysts.
How is Kyntra Bio's target upside or downside calculated?
The average target of $38.50 is divided by the recorded price of $4.85, then one is subtracted to produce +693.8%. This does not guarantee a future return.
When was Kyntra Bio's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.